Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Sloan Pharma S.à.r.l., 33, Rue du Puits Romain, 8070 Bertrange, Luxembourg
NeuroBloc 5000 U/ml solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear and colourless to light yellow solution. |
Each ml contains 5000 U Botulinum Toxin Type B.
Each 0.5 ml vial contains 2500 U Botulinum Toxin Type B.
Each 1.0 ml vial contains 5000 U Botulinum Toxin Type B.
Each 2.0 ml vial contains 10,000 U Botulinum Toxin Type B.
Produced in Clostridium botulinum Serotype B (Bean Strain) cells.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Botulinum toxin type B |
Botulinum toxin type B is a neuromuscular blocking agent indicated for the treatment of cervical dystonia. When injected directly into a muscle, it causes a localised paralysis that gradually reverses over time. |
| List of Excipients |
|---|
|
Disodium succinate |
0.5 ml, 1 ml or 2 ml solution in a 3.5 ml Type I glass vial, with siliconised butyl rubber stoppers oversealed by aluminium crimped caps.
Pack size of 1.
Sloan Pharma S.à.r.l., 33, Rue du Puits Romain, 8070 Bertrange, Luxembourg
EU/1/00/166/001 – 2500 U
EU/1/00/166/002 – 5000 U
EU/1/00/166/003 – 10,000 U
Date of first authorisation: 22 January 2001
Date of latest renewal: 29 November 2010
| Drug | Countries | |
|---|---|---|
| NEUROBLOC | Austria, Cyprus, Estonia, Spain, Finland, France, Ireland, Lithuania, Poland, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
